Boston Trust Walden Corp Has $41.52 Million Stake in Becton, Dickinson and Company $BDX

Boston Trust Walden Corp decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 30.2% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 241,036 shares of the medical instruments supplier’s stock after selling 104,146 shares during the period. Boston Trust Walden Corp’s holdings in Becton, Dickinson and Company were worth $41,518,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BDX. GQG Partners LLC acquired a new position in Becton, Dickinson and Company in the first quarter valued at $689,833,000. Vanguard Group Inc. lifted its holdings in Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after buying an additional 1,259,750 shares during the period. Nuveen LLC acquired a new position in Becton, Dickinson and Company in the first quarter valued at $211,097,000. Kingstone Capital Partners Texas LLC bought a new stake in Becton, Dickinson and Company in the second quarter valued at $155,080,000. Finally, Massachusetts Financial Services Co. MA increased its stake in Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after purchasing an additional 667,957 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the company’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company’s stock, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock valued at $562,036 over the last ninety days. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Trading Up 0.9%

NYSE:BDX opened at $188.31 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a 50-day moving average of $190.46 and a 200-day moving average of $185.47. The company has a market cap of $53.97 billion, a PE ratio of 33.87, a PEG ratio of 1.46 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. As a group, equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is presently 74.82%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on BDX shares. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Argus lifted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Royal Bank Of Canada started coverage on shares of Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 price target for the company. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus target price of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.